The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Apitope announced positive results from the Phase I first in man clinical trial of its product candidate, ATX-GD-59, in development for the treatment ...
read more
BioAtla announced the FDA has cleared BioAtla's IND for BA3021, a first-in-class conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-...
read more
Alkermes announced that the FDA has accepted for review the NDA for ALKS 5461, a novel, once-daily, oral investigational medicine for the adjunctive ...
read more
UCB announced an agreement to acquire the rights to Proximagen's Midazolam Nasal Spray, an AED developed as an intended rescue treatment for acute ...
read more
Nektar has entered into a new clinical collaboration with Takeda to evaluate NKTR-214 with TAK-659 as a potential combination treatment regimen in ...
read more
Lin BioScience announced the FDA has granted Orphan Drug Designation to LBS-007 for acute lymphoblastic leukemia.
read more
Wednesday, April 25, 2018
Following successful Phase 1 clinical trials of a new immunotherapy for patients with recurrent brain cancer, the Toca regimen trial has advanced to a...
read more
Sangamo announced the California Institute for Regenerative Medicine has awarded an $8 million grant for Sangamo to evaluate ST-400.
read more
Arena and Outpost Medicine announced they have entered into a licensing agreement to advance an undisclosed, preclinical compound with potential ...
read more
Merck KGaA, Darmstadt, Germany announced a development agreement for investigational molecule abituzumab with SFJ Pharmaceuticals Group.
read more
Forty Seven announced the FDA has granted two Fast Track designations to its lead candidate, 5F9, for the treatment of relapsed or refractory DLBCL ...
read more
PaxVax has received Fast Track designation from the FDA for its vaccine for the prevention of disease caused by the chikungunya virus.
read more
Debiopharm announced the FDA has granted Fast Track designation to Debio 1347, an FGFR 1-3 Inhibitor, for the treatment of patients with unresectable ...
read more
Nektar Therapeutics has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b clinical study evaluating NKTR-358, a first-in...
read more
Taiho Oncology and Servier announced the pivotal Phase 3 trial evaluating LONSURF plus best supportive care versus placebo plus BSC in patients with ...
read more